PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma

Landon C. Brown, Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, Zuowei Su, Shannon McCall, Jiaoti Huang, Wen Chi Foo, Rajan T. Gupta, Andrew J. Armstrong, Daniel J. George, Michael R. Harrison, Tian Zhang

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Few studies have evaluated concordance between different commercially available programmed death-ligand 1 (PD-L1) assays. Tissue from 32 patients with metastatic renal cell carcinoma and 18 patients with metastatic urothelial carcinoma were assessed by 2 different PD-L1 assays each and found 91% and 94% concordance between assays, respectively. These results suggest strong concordance and similar performance characteristics across PD-L1 assays.

Original languageEnglish (US)
Pages (from-to)509-513
Number of pages5
JournalClinical Genitourinary Cancer
Volume18
Issue number6
DOIs
StatePublished - Dec 2020
Externally publishedYes

Keywords

  • Biomarkers
  • Dako
  • Immunohistochemistry
  • Immunotherapy
  • Programmed death receptor-1

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this